Garda Capital Partners has launched a cash tender offer to acquire all outstanding shares of Assertio Therapeutics at $18.00 per share, valuing the specialty pharmaceutical company at $125.1 million. The offer represents a 27% premium to Assertio's thirty-day volume-weighted average price before the announcement. The tender commenced this week with an expected close in forty-five to sixty days, subject to standard HSR clearance and minimum tender conditions.

Assertio trades a concentrated portfolio of seven branded pain products, anchored by Indocin, Cambia, and Sprix—legacy assets with declining primary-care footprints. The company reported $145 million in trailing twelve-month revenue through September 2024, down 8% year-over-year, with EBITDA margins compressing to 22% from 28% two years prior. Management attributed the slide to generic erosion in the migraine segment and reduced physician detailing budgets. The equity had traded in a $12-$16 band since its 2020 separation from Zyla Life Sciences, never recovering the $24 book value established at spinoff. Garda's offer clears the board at a modest 1.4x trailing sales multiple, below the 2.1x median for specialty pharma takeouts since 2022.

The transaction removes a chronic underperformer from public markets while handing Garda a stable cash-generating base for bolt-on acquisitions in the overlooked pain-management channel. Assertio's products carry high gross margins—83% on branded generics—but require minimal R&D spend, making them ideal balance-sheet filler for a private platform. Garda, known for operational turnarounds in healthcare services, likely sees $18-$22 million in annual cost savings by collapsing public-company overhead, eliminating investor relations, and renegotiating commercial contracts with the three large PBMs that control 71% of Assertio's volume. The firm has not disclosed its financing structure, but the deal size suggests a mix of fund equity and senior debt at 4.5-5.0x levered EBITDA—conservative by 2021 standards, disciplined by today's.

For single-family offices holding microcap pharma, the tender exposes the widening bid-ask spread between public valuations and private-market clearing prices. Assertio traded at $14.20 as recently as December 2024, implying a 27% arbitrage gap that institutional desks could not close. The stock's average daily volume of 180,000 shares meant any meaningful accumulation would have moved the tape, while activist campaigns required proxy infrastructure few funds could justify for a $98 million market cap. Garda's entry confirms that sub-$200 million healthcare equities now trade at distressed multiples unless a strategic buyer or family office steps in with all-cash certainty. The tender also signals renewed interest in mature pharma assets with predictable, if modest, cash flows—a shift from the growth-at-any-cost biopharma bets that dominated 2020-2021 allocations.

Operators should monitor the tender's minimum condition, typically 50-67% of outstanding shares, and watch for any topping bid from generic manufacturers seeking to verticalize their pain portfolios. Amneal and Hikma have both pursued similar tuck-ins in the past eighteen months. The $18 price leaves $3-$4 per share of upward optionality if a second bidder emerges, though Assertio's staggered board and poison pill—adopted in 2022—make hostile interference unlikely. Closing is expected by mid-March 2025, with Assertio delisting from Nasdaq shortly thereafter.

Garda's tender ends Assertio's four-year public run at the precise moment when cost of capital and regulatory patience for sub-scale pharma both ran out.